Mesalazina Eg

Mesalazine, the active ingredient in Mesalazina Eg, is an aminosalicylate presented as a rectal formulation for local use in the colon. It is employed to reduce inflammation associated with ulcerative colitis and proctitis, providing targeted symptom relief for patients with inflammatory bowel disease.

GNH USA supplies Mesalazina Eg, an EU‑origin product, as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Mesalazine acts locally in the colon to treat inflammatory bowel disease conditions.

Ulcerative colitis: reduces mucosal inflammation and helps maintain remission. Proctitis: alleviates rectal inflammation and improves bowel symptoms. Maintenance therapy: supports long‑term disease control in ulcerative colitis patients.

Mesalazine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Rectal irritation or burning sensation - Abdominal pain or cramping - Nausea or mild vomiting - Headache or dizziness

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, rash, swelling) - Blood in stool or severe colitis - Elevated liver enzymes or hepatitis - Pancreatitis or toxic megacolon

Before initiating therapy, consider the following safety measures.

Pregnancy: safety not established; use only if benefit outweighs risk. Renal impairment: monitor renal function regularly. Hepatic impairment: use with caution and assess liver enzymes. Concurrent infection: evaluate risk of worsening infection. Store at room temperature: keep in original packaging, protect from moisture and light.

Mesalazine can interact with several medicines; monitor patients accordingly.

Major Interactions (Avoid): - Azathioprine: increased risk of bone‑marrow suppression. - Methotrexate: additive hepatotoxicity potential. - Warfarin: may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in efficacy. - NSAIDs: increased gastrointestinal irritation.